Navigation Links
Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Date:8/10/2009

PALO ALTO, Calif., Aug. 10, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

CLEAN-1 will evaluate the safety and antiviral activity of clemizole, a first generation antihistamine, in 28 days of oral therapy in treatment-naive patients infected with HCV genotypes 1 and 2. This direct antiviral study represents an important first step in evaluating the therapeutic potential of inhibiting a new target in HCV -- small molecule inhibition of the interaction between NS4B and HCV-RNA that is required for HCV replication.

"This proof of concept study is an important first step in our comprehensive development strategy for clemizole and newly discovered NS4B-RNA binding inhibitors for the treatment of HCV," said David Cory, President and CEO of Eiger. "Inhibiting the NS4B-RNA interaction represents an exciting new approach toward developing interferon-free, virus-specific agents to treat HCV."

Eiger BioPharmaceuticals recently announced the acquisition of the exclusive license to this novel HCV technology, discovered in the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues. Clemizole targets a non-structural protein found in the HCV genome, NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein represents a new approach to treat HCV infection and may be associated with less drug resistance than polymerase and protease inhibitors in development.

About NS4B and Clemiz
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
2. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
5. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
11. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Research presented at the American College of Allergy, Asthma ... intervention to reduce over-dispensing and waste of asthma medications ... in substantial cost savings. , Medco Health Solutions, Inc. ... study that examined the effectiveness and safety of a ...
... -- New research findings presented today at ... Conference in New York show promise in assessing ... medicine (CAM) using traditional research methods. Susan Sencer, ... Clinics of Minnesota (Children,s), presented findings on the ...
Cached Medicine Technology:New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
(Date:4/17/2014)... alleviates muscle soreness after exercise, according to a ... at Chicago. , The study, reported online in ... Physical Medicine and Rehabilitation , also showed that ... not exercised, suggesting that massage has benefits for ... , Improved circulation and relief of muscle soreness ...
(Date:4/17/2014)... patients adrenaline after they suffer a cardiac arrest outside ... surviving long-term, according to new research conducted at St. ... have a cardiac arrest get adrenaline, which has been ... said Dr. Steve Lin, an emergency physician and trauma ... medical treatment, long-term survival rates of patients who suffer ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... Pradesh took part in an AIDS awareness campaign and vowed ... ,The students tied 'suraksha bandhan' (protection bands) on their ... commitment to spread this awareness. ,The students were ... Journalism here as part of a 'Unite for Children, Unite ...
... some brands of frozen ready meals including 20 Asda own ... fears that they may contain small pieces of glass. Customers ... ,The products came from Rye Valley Foods ... are one of the country's biggest food processors. The company ...
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... plausible culprit for rendering sick nearly 260 Tewksbury students, ... stomach virus// has allegedly gripped several of the students ... not about to spare anyone- teachers, parents and siblings ... us to keep everything clean,” said Sue McLaughlin, co-chairwoman ...
... treated for ovarian cancer are at increased risk of ... cells have high// levels of a binding protein that ... hallmarks of malignancy. ,“Now there’s the possibility ... during surgery might identify women most at risk for ...
... or painful breast tissue, but the majority do not ... Center. // Mammograms are used to check for the ... males. ,Their study, presented Saturday, Dec. 16, at ... Symposium, suggests physicians should reconsider ordering mammograms for men, ...
Cached Medicine News:Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2Health News:Use of Mammograms in Men 2
Plastic Citrate Tube, .109M / 3.2%...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Inquire...
... EDTA K2 / gel tubes ... plasma for molecular diagnostics and for ... in whole blood remain stable at ... hours. For optimal results, it is ...
Medicine Products: